Mutations Associated with Imatinib Mesylate Resistance - Review

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Chronic myeloid leukemia (CML) is driven by the Philadelphia chromosome (Ph), a result of BCR-ABL1 gene fusion.
• Imatinib mesylate, a tyrosine kinase inhibitor (TKI), is a primary CML treatment.
• BCR-ABL1 kinase domain mutations confer resistance to TKIs.

Purpose of the Study:

• To review mutations in BCR-ABL1 kinase domain associated with CML resistance.
• To discuss the clinical significance of early mutation detection.
• To explore emerging TKIs and their efficacy against resistant mutations.

Main Methods:

• Literature review of studies on CML, BCR-ABL1 mutations, and TKI resistance.
• Analysis of identified mutations and their impact on treatment response.
• Evaluation of novel TKI development and resistance profiles.

Main Results:

• Over 40 distinct BCR-ABL1 mutations have been identified, leading to imatinib resistance.
• Mutation analysis is crucial for guiding CML treatment decisions.
• Newer TKIs demonstrate varying efficacy against specific mutations, offering alternative therapeutic options.

Conclusions:

• BCR-ABL1 mutations are a significant mechanism of CML treatment failure.
• Personalized therapy using TKIs tailored to specific mutations is essential.
• Ongoing research into novel TKIs is vital for managing resistant CML.